Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    Ocrelizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche's high-dose version of Ocrevus flunks phase 3 trial
    Roche's high-dose version of Ocrevus flunks phase 3 trial

    03 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biosimilar-competition-looming-roche-takes-hit-failure-high-dose-ocrevus

    FIERCE PHARMA
    03 Apr 2025
    Share Share
    Genentech Updates Ocrevus High Dose Study in Multiple Sclerosis
    Genentech Updates Ocrevus High Dose Study in Multiple Sclerosis

    02 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250402207576/en/Genentech-Provides-Update-on-Phase-III-Ocrevus-High-Dose-Study-in-People-With-Relapsing-Multiple-Sclerosis

    BUSINESSWIRE
    02 Apr 2025
    Share Share
    Genentech`s Biologic Ocrevus (Ocrelizumab) Receives Approval in US
    Genentech`s Biologic Ocrevus (Ocrelizumab) Receives Approval in US

    13 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761371

    FDA
    13 Sep 2024
    Share Share
    FDA Approves Roche's Subcutaneous OCREVUS ZUNOVO With ENHANZE
    FDA Approves Roche's Subcutaneous OCREVUS ZUNOVO With ENHANZE

    13 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-subcutaneous-ocrevus-zunovo-with-enhanze-for-people-with-relapsing-and-primary-progressive-multiple-sclerosis-302247928.html

    PR NEWSWIRE
    13 Sep 2024
    Share Share
    NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis
    NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis

    12 Jul 2024

    // Robert Barrie PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/nhs-rolls-out-more-convenient-ocrevus-injection-for-multiple-sclerosis/

    Robert Barrie PHARMACEUTICAL-TECHNOLOGY
    12 Jul 2024
    Share Share
    Genentech Inc Biologic Ocrelizumab Receives Approval in US
    Genentech Inc Biologic Ocrelizumab Receives Approval in US

    21 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053

    FDA
    21 Jun 2024
    Share Share